secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-002563
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir reduces workforce by ~95%; expects $13M in severance charges
--------------------------------------------------------------------

- Board approved cutting ~95% of employees to preserve capital after discontinuing three global Phase 3 posoleucel studies (announced Dec 22, 2023).
- Reduction primarily in Q1 2024, substantially complete by April 15, 2024.
- Expects ~$13M in personnel-related restructuring charges (severance and benefits) largely incurred in Q1 2024.
- Additional charges may arise from retention efforts or other events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/0001193125-24-002563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524002563/d35101d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer